This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Compelling Weight Management Program Data Set to Boost CVS Stock
by Zacks Equity Research
CVS Health shares impressive findings from its Weight Management Program.
CVS Health (CVS) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CVS Health (CVS) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, CVS Health (CVS) stood at $65.75, denoting a +1.4% change from the preceding trading day.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Stock Soars 47% YTD: Is Digital Growth Fueling a Buy Opportunity?
by Urmimala Biswas
CVS Health is consistently increasing investments in fast-growing spaces like enterprise data platforms, cloud capabilities and digital products.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Is First Trust Large Cap Value AlphaDEX ETF (FTA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTA
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
5 Best Stocks Powering S&P 500 ETF Midway in Q1
by Sweta Killa
The S&P 500 hit a new all-time high on Feb. 18. We highlight five stocks in SPY that are leading midway through Q1.
CVS Health Post-Q4 Earnings: Is the Stock Worth Buying Now?
by Urmimala Biswas
CVS Health's adjusted EPS outlook for 2025 reflects expectations of a meaningful recovery in Medicare Advantage and continued growth in Health Services.
Moody's Downgrades WBA's Outlook: Should You Hold or Sell the Stock?
by Moumi Mondal
Despite Moody's latest negative rating, Walgreens' focus on operational turnaround and improving cash flows makes it a good hold.
Zacks Earnings Trends Highlights: Coca-Cola, CVS, Pepsi and Walgreens Boots Alliance
by Zacks Equity Research
Coca-Cola, CVS, Pepsi and Walgreens Boots Alliance have been highlighted in this Earnings Trends article.
Breaking Down the Current Earnings Outlook
by Sheraz Mian
We can safely say that it has been a good reporting cycle, with the growth pace showing a notable accelerating trend and companies comfortably beating consensus estimates. But what about the coming periods?
Breaking Down the Current Earnings Outlook
by Sheraz Mian
We can safely say that it has been a good reporting cycle, with the growth pace showing a notable accelerating trend and companies comfortably beating consensus estimates. But what about the coming periods?
CVS Health (CVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
by Zacks Equity Research
CVS tops earnings and revenue estimates in the fourth quarter of 2024 amid macroeconomic impacts in the Health Care Benefits arm.
CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 33.71% and 0.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Seeking Clues to CVS Health (CVS) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Avantor, Inc. (AVTR) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Avantor (AVTR) delivered earnings and revenue surprises of 8% and 1.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
CVS Health (CVS) reachead $55.69 at the closing of the latest trading day, reflecting a -1.17% change compared to its last close.
Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health's Pre-Q4 Earnings: Time to Buy, Hold or Sell the Stock?
by Urmimala Biswas
Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.